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Elite controllers maintain HIV-1 viral loads below the limit of detection. The mechanisms responsible for
this phenomenon are poorly understood. As microRNAs (miRNAs) are regulators of gene expression and
some of them modulate HIV infection, we have studied the miRNA profile in plasma from HIV elite
controllers and chronically infected individuals and compared against healthy donors. Several miRNAs
correlate with CD41 T cell count or with the known time of infection. No significant differences were
observed between elite controllers and healthy donors; however, 16 miRNAs were different in the plasma of
chronic infected versus healthy donors. In addition, levels of hsa-miR-29b-3p, hsa-miR-33a-5p and
hsa-miR-146a-5p were higher in plasma from elite controllers than chronic infected and hsa-miR-29b-3p
and hsa-miR-33a-5p overexpression significantly reduced the viral production in MT2 and primary T
CD41 cells. Therefore, levels of circulating miRNAs might be of diagnostic and/or prognostic value for HIV
infection, and hsa-miR-29b-3p and miR-33a-5p may contribute to the design of new anti-HIV drugs.
I
nfection with HIV is characterized by a progressive decrease of CD41 T lymphocytes and immune dysfunc-
tions that ultimately lead to AIDS. However, between 1% to 5% of people infected with HIV, known as long-
term nonprogressors: (LTNP), are able to maintain stable CD41T cell counts, showing important variations
in their viremia levels1,2. Furthermore, a rare subgroup among these LTNP, termed ‘‘elite suppressors’’ or ‘‘elite
controllers’’ (EC), maintain plasma viral loads below the limit of detection of commercial assays (50 copies/ml)
and usually do not show any clinical signs of disease progression for many years3,4.
Several studies have shown that not only viral characteristics such as mutations or deletions in viral proteins
like Gag, Nef, and other accessory proteins were associated to a disease control5–7, but also that host specific
immunological determinants and genetic background are related to elite suppression of viral replication8, since
replication-competent viruses have been isolated from EC9,10. Examples of such genetic differences include
specific expression of HLA class I complex, mutations in the gene for the human chemokine receptor 5
(CCR5) or the functionality of T CD81 lymphocytes11–13. Nevertheless, it is unlikely that only these variations
can explain the remarkable immune response of EC against HIV infection.
Interestingly, Witwer et al. recently revealed notable similarities in microRNA (miRNA) profiles between
peripheral mononuclear cells (PBMC) from EC and healthy donors when compared to viremic HIV patients14.
This suggests that intracellular miRNAs might be implicated in the particular antiretroviral-free control of HIV
infection. MiRNAs are small (18–24 bp) non-coding RNAs, which have important regulatory roles in the cells by
silencing mRNA expression through the interaction with the RNA-induced silencing complex (RISC), resulting
in mRNA cleavage or translational repression15. The ability of miRNAs to bind and repress the translation of up to
hundreds of mRNAs establishes miRNAs as central regulators of gene expression with important biological roles
including the regulation of antiviral defenses16. In addition, miRNAs that are encapsulated by microvesicles or
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concentration profile of miRNAs in plasma/serum has been pro-
posed as a useful tool for diagnosis and prognosis of several diseases
including cancer or cardiovascular diseases18–21.
Consequently, we hypothesized that a specific signature of
miRNAs in plasma/serum might discriminate elite controllers from
patients with chronic HIV infection. In addition, since it has been
shown that HIV replication can be modulated by the expression of
human miRNAs22,23, we also hypothesized that such miRNAs might
be involved in controlling HIV infection. This assumption seemed
conceivable, since miRNAs are also known to be transferred to
recipient cells, where they are actively controlling gene expression17.
Thus, we set out to profile 175 miRNAs in plasma derived from
EC, chronic HIV progressors (CH) and healthy donors (HD).
Thereby, we discovered 16 differentially expressed miRNAs between
CH and HD, and 3 between CH and EC. We then tested, if these latter
three miRNAs influence the replication of HIV in lymphocytes as in
vitro model system, and indeed observed that hsa-miR-29b-3p and
hsa-miR-33a-5p overexpression significantly reduced virus produc-
tion. Finally, levels of these miRNAs in plasma samples from treat-
ment-naive HIV infected patients were analysed to find a similar
response as in chronic HIV patients undergoing anti-retroviral treat-
ment (ART). Therefore, we suggest that plasma derived miRNA
signatures might be of prognostic value for HIV, but also for viral
infections in general. In addition, hsa-miR-29b-3p and miR-33a-5p
might be used in developing therapeutic strategies against HIV.
Results
Donor characteristics. We studied the expression levels of circulat-
ing miRNAs in EDTA-plasma samples derived from 27 subjects, 10
CH, 10 EC and 7 HD. Stringent quality criteria were applied in order
to avoid bias introduced during sample preparation including RNA
isolation, cDNA synthesis and qPCR (see Material and Methods,
Supplemental figure 1). Consequently, 9 samples from EC, 9 CH
and 6 HD were included in the analysis. One sample from the CH
group was excluded from the analysis due to a very specific liver
toxicity profile, which we regarded as confounding to our aims.
This liver toxicity is explained by co-infection of the patient with
Hepatitis B virus and was detected due to high levels of hsa-miR-194
and hsa-miR-122 as described24,25 (Supplemental figure 1d).
The characteristics of the donors included in this study are sum-
marized in Table 1. There were no differences between the groups
regarding age and gender (p 5 0.790 and p 5 0.862 respectively).
CD41 T cell counts and the known time of infection did not stat-
istically differ between EC and CH (p 5 0.298 and p 5 0.722 respect-
ively). The viral load was below 50 copies/ml in all the samples of the
EC group and in 8 of the CH group, in which one mounted to
568 copies/ml.
MiRNA plasma profiles discriminate chronically infected
patients. In total 175 miRNAs were analyzed in this study using
the miRCURY LNATM Serum/Plasma Focus PCR panel. On
Figure 1 | Explorative data analysis. (A) Principal components analysis of miRNAs profile in plasma was done on all miRNAs. The normalized Cp values
were used for the analysis. The x-axis corresponds to principal component 1 (PC1) and the y-axis to the principal component 2 (PC2), the percentage of
the variance is indicated between brackets. (B) Heatmap and hierarchical clustering. The clustering is performed on all the samples and the 96
miRNAs expressed in all the samples, using complete linkage and Euclidean distance as distance metric. Each column represents one sample and each row
one miRNA. The miRNA clustering tree is shown on the left. The color-coded scale (blue: expression levels lower than the mean and red: expression level
over the mean) for the normalized expression value is indicated at the top of the figure.
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average, 153 miRNAs were detected per sample and 96 miRNAs gave
reliable signals in all 23 samples (Supplemental File 1). In the first
step, an exploratory data analysis was performed in order to evaluate
grouping of studied samples according to their disease state and to
identify co-regulated sets of miRNAs. Therefore, a principal
component analysis (PCA) was performed with the intention of
reducing the dimensionality of the data set from 175 miRNAs to
two dimensions (PC1 and PC2), accounting for more than 60% of
the variability in the data set. Indeed, PCA revealed that EC and HD
have similarities, and that they both are clearly separated from CH
samples, indicating that miRNAs might be valuable discriminators
between the groups. This was supported by unsupervised
hierarchically clustering using Euclidean distance and complete
linkage analysis based on the set of 96 miRNAs present in all
samples. Thereby, the majority of EC fall together into one cluster
and are clearly separated from the cluster containing samples
from CH (Figure 1b). Samples representing HD partly cluster
with EC samples or are represented in an independent cluster to
the right. Overall, these data strongly suggest that miRNA profiles
in plasma samples from EC are different from the observed in
patients with chronic HIV infection and, in some instances, similar
to that of HD.
MiRNA levels are altered in plasma of HIV patients. To further
identify differentially expressed miRNAs between the groups, we
compared the relative miRNA expression (dCp) applying ANOVA
followed by post-hoc Bonferroni test. We found 49 miRNAs
differentially expressed between the groups, suggesting that HIV
infection strongly influences the plasma miRNA profile (Supple-
mental table 1). After correction for false positive discovery rate
(FDR) in multiple comparisons using the Hochberg test, 16
miRNAs passed the p-value adjustment and were identified
significantly different between CH and HD (Table 2). In addition,
plasma levels of hsa-miR-29b-3p, hsa-miR-33a-5p and hsa-miR-
146a-5p were different between CH and EC (Figure 2a). As shown
in the Venn diagram hsa-miR-29b-3p and hsa-miR-33a-5p were also
found differentially expressed between CH and HD, while no signi-
ficant differences were observed between EC and HD (Figure 2b).
Next, we wanted to test whether the expression of these miRNAs is
also modified in plasma from patients with progressive disease and
without ART. Therefore, 20 plasma samples from untreated patients
(PVL mean: 124077 6 146560 copies/ml, CD41 T cell count mean:
108 6 102 cells/ml) were obtained and the levels of circulating hsa-
miR-29b-3p, hsa-miR-33a-5p and hsa-miR-146a-5p were analyzed
by qPCR. Again the expression levels of hsa-miR-29b-3p and hsa-
Table 1 | Donors characteristics
Chronic HIV ELITE Controllers Healthy donors
n 9 9 6
Gender (male5female) 455 356 254
Age (years) 42.9 6 7.5* 42.1 6 7.7* 35.6 6 13.8*
CD41 T cell count 447.8 6 227.7* 630 6 159.5* NA
Viral load (copies/ml) ,50{ ,50{ X
CD81 T cell count NA 835.4 6 549.1* NA
Known time of infection (years) 8.4 6 4.9* 7.4 6 4.3* X
Coinfections (n)# 3 0 X
Opportunistic infections (n) 3 0 X
ART (n) 7/8 0 X
X: not applicable, NA: not available,
*mean 6 SD,
{ median # Hepatitis C or B virus, ART: Antiretroviral therapy.
Table 2 | Differentially-expressed miRNAs after applying Benjamini-Hochberg correction
Log2 expression* Significance (q value)
Name Chronic Elite Normal CH vs. EC CH vs. HD EC vs. HD
hsa-miR-33a-5p 22.381 21.073 21.119 0.030 0.024 NS
hsa-miR-146a-5p 20.309 0.732 0.340 0.053 NS NS
hsa-miR-660-5p 23.976 24.620 25.102 NS 0.016 NS
hsa-miR-151a-5p 1.201 1.529 1.849 NS 0.017 NS
hsa-miR-29b-3p 22.890 22.111 22.204 0.030 0.029 NS
hsa-miR-28-5p 21.008 20.782 20.368 NS 0.009 NS
hsa-miR-191-5p 1.341 2.012 2.171 NS 0.039 NS
hsa-miR-181a-5p 0.160 1.060 1.730 NS 0.029 NS
hsa-miR-18b-5p 20.344 0.202 0.435 NS 0.047 NS
hsa-miR-126-3p 4.564 5.038 5.150 NS 0.017 NS
hsa-miR-423-3p 0.744 1.331 1.783 NS 0.033 NS
hsa-miR-18a-5p 21.009 20.380 20.302 NS 0.049 NS
hsa-let-7i-5p 20.152 0.158 0.569 NS 0.029 NS
hsa-miR-19b-3p 4.561 4.535 3.899 NS 0.016 NS
hsa-miR-342-3p 20.013 20.864 21.557 NS 0.029 NS
hsa-miR-424-5p 20.112 20.633 21.092 NS 0.029 NS
hsa-miR-16-5p 4.808 4.410 4.077 NS 0.017 NS
*dCp: normalized crossing point (log2 miRNA expression).
q Value: Significance calculated from p values of Post-hoc Bonferroni using Benjamini – Hochberg false discovery rate test.
NS: not significant (q . 0.05).
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miR-33a-5p were significantly lower in samples from patients with
HIV comparing to HD (p 5 0.0413 and p 5 0.0014 respectively)
(Supplemental Figure 2).
Together, these results indicate that HIV infection influences
levels of specific miRNAs in the blood, which is independent of
ART in case of hsa-miR-29b-3p and hsa-miR-33a-5p.
Specific miRNAs in plasma correlate with T CD41 cell count and
the known time of infection. After discovering differences in the
miRNA plasma profile between the groups, we were interested in
finding out relations between the levels of miRNA expression in
plasma and specific clinical parameters. Interestingly, we found
that hsa-miR-18b-5p, hsa-miR-126-3p, hsa-let-7d-3p and hsa-
miR-18a-5p correlated positively with CD41 T cell counts (p 5
0.015, p 5 0.024, p 5 0.011, and p 5 0.033 respectively). On the
other hand, hsa-miR-424-5p and hsa-miR-34a-5p correlated
negatively (p 5 0.006 and p 5 0.01 respectively; Figure 3a). In
addition, we observed that hsa-miR-766-3p and hsa-miR-301a-3p
correlate positively and hsa-miR-126-3p negatively with the known
time of infection (Figure 3b), whereby the correlation of miR-766-3p
is the most striking as it linearly increases over time. Despite the small
sample size, these observations strongly suggest that the expression
Figure 2 | Differentially-expressed miRNAs. (A) Dot plot showing miRNAs differentially expressed between EC and CH. Each dot indicates the
individual level of expression and the line is representing the mean of the group. Asterisks indicate a q value # 0.05. (B) Venn diagram showing the
overlapping of the differentially expressed miRNAs. HD: healthy donors, EC: elite controllers, CH: chronic HIV.
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levels of specific miRNAs are related to CD41 T cell count and
additionally the levels of some miRNAs would be modified during
the progression of HIV infection.
Hsa-miR-29b-3p and hsa-miR-33a interfere with HIV replication
in vitro. Since several reports have shown that circulating miRNAs
can be functionally transferred to recipient cells, we tested, if the 3
differentially expressed miRNAs in plasma of EC versus CH (down-
regulated in CH) might influence HIV replication in vitro. Therefore,
we pre-transfected these miRNAs and a scrambled non-targeting
control miRNA into MT2 as model for T-cells and subsequently
into primary CD4 T cells, where hsa-miR-10a was used as putative
non-functional control, since it was not found to be differentially
present in plasma samples, together with non-infected cells
(Figure 4). Transfection efficiency in CD4 cells was controlled
using Cy-3 labelled miRNA mimics (Supplemental Figure 3) and
microRNA overexpression was evaluated 48 hours post
transfection by qPCR (Figure 4 A–B). After miRNA transfection,
cells were in turn infected with HIV-NL4.3. The viral replication
was quantified by ELISA of p24 in cell supernatants over 9 days
(MT2) or 11 days (CD4) (Figure 4 C,D).
Since hsa-miR-146a-5p is known to down-regulate the CXCR4
receptor involved in infection by HIV (26) we tested this miRNA
first. However, no inhibition of HIV infection was observed. When
testing CXCR4 expression after miR-146-5p transfection in MT2
cells by flow cytometry, no reduction of CXCR4 was observed
(Supplemental Table 2), potentially accounting for its lack of inhib-
itory activity on HIV infection. In contrast, the other two miRNAs,
hsa-miR-29b-3p as well as hsa-miR-33a-5p significantly decreased
p24 in the cellular supernatants as compared to non-targeting con-
trol transfected cells (MT2 cells: hsa-miR-29b-3p p , 0.001 and hsa-
miR-33a-5p p , 0.001; primary CD4-positive cells: hsa-miR-29b-3p
p 5 0.03 and hsa-miR-33a-5p p 5 0.019) (Figure 4 C,D). Combining
hsa-miR-29b-3p and hsa-miR-33a-5p had no synergistically inhib-
itory effect on the viral replication (data not shown). These results
suggest that miRNAs present in the blood of elite controllers at
higher levels than in chronically diseased individuals might contrib-
ute to a successful defence against HIV progression to AIDS.
Figure 3 | miRNAs correlated with T CD41 cell count and known time of infection. (A) Six miRNAs were found to be correlated with T CD41 cell
count. (B) Three miRNAs were correlated with known time of infection in years. The analysis was performed considering all the HIV infected samples.
PCC: Pearson correlation coefficient, p: p value. The p values indicate the significance of the Pearson correlation. .: chronic HIV, m: elite controllers.
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Discussion
Here we describe differences in the plasma miRNA signatures of HIV
infected individuals. We show that 16 miRNAs are differentially
expressed between CH and HD. Interestingly, some of these
miRNAs have been previously reported to play a role either in HIV
infection or in the functionality of the immune system. For example,
hsa-miR-28-5p belongs to the cluster of cellular anti-HIV miRNAs
that induce the viral latency in CD41 T cells and also inhibits viral
replication in monocytes/macrophages22,23,26. In addition, hsa-miR-
181a-5p is associated to the regulation of T cell development and
inflammatory responses of monocytes/macrophages27,28. Therefore,
the down-regulation of these miRNAs by HIV might be one of the
mechanisms associated to disease progression.
But where do these miRNAs in the plasma come from? Previous
investigations of blood cells indicate that HIV infection -both in vivo
and in vitro- affects the expression of miRNAs in various immune
cells14,29–32, and that these cells are able to secrete miRNAs depending
on various conditions33,34. This would suggest that blood cells are an
Figure 4 | miRNAs interfere with HIV replication. (A) Real-time qPCR analysis of hsa-miR-29b-3p, hsa-miR-33a-5p and hsa-miR-146a was performed
48 hours post transfection in MT2 cells. Two independent reference genes (U6 and 5S rRNA) were used for normalization and fold changes in miRNA
levels relative to a scrambled negative control miRNA (fold-change 5 1, not shown) were calculated as average from 3 independent transfections (1/
2SD). (B) Analogous qPCR data for CD4 cells. hsa-miR-10a was included in this experiment as non-functional negative control, since it was not
differentially present in plasma samples of CH, EC and HD. (C) Forty eight hours after transfection MT2 cells were infected with HIV-NL4.3. p24 antigen
titers are given in ng/ml at day 9 post infection of MT2 cells. (D) p24 antigen titers from supernatant of primary CD4-positive T cells at day 11 after
infection with HIV. As shown, the overexpression of hsa-miR-29b-3p and hsa-miR-33a-5p reduce significantly the production of p24 antigen (MT2 cells:
hsa-miR-29b-3p p , 0.001 and hsa-miR-33a-5p p , 0.001; primary CD4-positive cells: hsa-miR-29b-3p p 5 0.03 and hsa-miR-33a-5p p 5 0.019). Three
independent infections after miRNA or scrambled-control transfections were performed and the respective p24 titers are shown for each infection as
average of two technical replicates.
Figure 5 | MiRNAs differentially expressed between EC and CH target
genes with important functions in HIV cycle. Hypothetical figure showing
how hsa-miR29b-3p, hsa-miR33a-5p and hsa-miR146a-5p could affect the
replication of HIV.
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active source of secretion, especially in the case of let-7d-3p, miR-
18a-5p, miR-18b-5p, miR-126-3p, and miR-424-5p that correlate
positively with T CD41 cell count. One miRNA, however, miR-
34a-5p is elevated in plasma when CD4 T cell counts get lower.
Since miR-34a-5p has been found to be high in CD41 T cells
in EC14, the negative correlation between T CD41 and plasma
miR-34a-3p levels might indicate that miR-34a-3p ends up in
the circulation due to CD41 T cell lysis. However, as miRNAs pre-
sent in plasma can derive from several cell types17,35, more work is
necessary to identify which miRNAs might originate from which cell
types.
We also find that some miRNAs correlate to the known time of
infection independently of CH or EC status of the patients. This
suggests that in CH the expression of plasma miRNAs might be
useful in predicting the disease progression and that the fight against
the virus adapts the organismal environment in a way that is mir-
rored by the circulating miRNAs. It is unclear, why EC display a
similar change in circulating miRNAs. Therefore, more studies, espe-
cially longitudinal studies, are necessary to establish the clinical rel-
evance of these findings.
Finally, the plasma miRNA profile can discriminate between EC
and CH. We show that the expression levels of hsa-miR-29b-3p, hsa-
miR-33a-5p and hsa-miR-146a-5p are higher in plasma from EC
than CH. This is in accordance to recent studies where intracellular
miRNA profiles in PBMC were found to discriminate EC and CH.
One miRNA, miR-29b, is found in both, PBMC and plasma14, as well
as the orthologous miRNA to the here described miR-146a-5p,
namely miR-146b-5p36. All other PBMC derived miRNAs, miR-
125b, miR-150 and miR-3114 and miR-15532 did not reach signifi-
cance in our setting.
In conclusion, the finding that the levels of hsa-miR29-3p, hsa-
miR-33a-5p and hsa-miR-146a-5p are higher in the plasma of EC
than in CH is striking, especially, if considering that miR-29b-3p is
known to target Nef37–39 and alterations in Nef functions have been
associated to slower progression to AIDS40,41. Similarly, hsa-miR-
146a-5p has been found to target CXCR442 and thus it could affect
HIV infection, while no connection of miR-33a and HIV infection
has been published so far. Since miRNAs that are found in plasma
can be taken up by immune cells35,43, we were intrigued by the
possibility that these miRNAs might also modify infection by
HIV in our setting. Indeed, miR-33a-5p and miR-29b-3p reduced
the production of p24 in vitro, while miR-146a-5p had no influence.
This lack of miR-146a-5p activity was mirrored by the fact that
CXCR4 was not knocked-down by in response to its overexpres-
sion under the conditions used here. Therefore more work is
needed to clarify whether miR-146a-5p has an effect in the immune
response or if it might interfere with HIV replication in vivo by
targeting CXCR4 as important co-receptor of the HIV entry route
into T cells.
How might the activity of miR-33a-5p be explained? We speculate
that the effect may be mediated by inhibition of MAPK8 (also known
as JNK), which is a validated target of this miRNA44 and described to
phosphorylate the viral integrase favouring the enzyme stability and
consequently an efficient integration of the proviral DNA45. These
data would suggest that all three miRNAs might be part of a ‘native’
anti-viral defence by targeting important steps during HIV infection
(Figure 5), since they are all found at higher levels in plasma of HD
and ECs. Their downregulation in CH might therefore either simply
be a consequence of the loss and premature aging of the immune
system, or an active mechanism of HIV to suppress the anti-viral
defence of the host.
Summarized, we propose that plasma miRNA profiling might be
used as diagnostic or prognostic markers in HIV pathogenesis and
disease progression. Moreover, hsa-miR-29b-3p and hsa-miR-33a-
5p, or mimicks thereof, might have the potential to be used in thera-
peutic strategies against HIV infection and AIDS.
Methods
Study population. Plasma samples were obtained from 27 subjects and were
classified in 3 groups, 10 Elite Controllers (EC), 10 chronic HIV patients (CH) under
ART and 7 healthy donors (HD) The group of the EC was defined as individuals with
plasma viral load (PVL) , 50 copies/ml, CD4 count . 350/ml. The PVL from EC
patients remain undetectable during the follow up period and CD4 cell counts were
stable for a period of at least 5 years. None of the patients developed opportunistic
infections or HIV associated conditions. The criteria for including patients in the
group with progressive disease were that patient reached a CD4 cell count lower than
350 cells/mL and/or developed opportunistic infections. The patients have been on
treatment for a mean time of 5 years [(Interquartile range (IQR) 2.5–8.5 years)] and
were aviremic for a mean time of 4.9 years (IQR 2.5–8). All of treated patients received
reverse transcriptase inhibitors, 50% received zidovudine, 90% lamivudine, 22%
tenofovir, 22% abacavir, 66% non-nucleoside reverse transcriptase inhibitors, 22%
protease inhibitors. In a second step, 20 patients with progressive HIV disease but
without ART were recruited. All the groups were chosen from the same population.
This study was approved by the Huésped Foundation Ethics Committee and
informed consent was obtained from all subjects. All experiments within this study
were performed in accordance with the Declaration of Helsinki.
Isolation of RNA from plasma. EDTA-blood samples were obtained by
venipuncture and plasma was separated by one centrifugation step at 2000 3 g for 10
minutes at room temperature (RT). All plasma samples were RNA spiked in with
3.5 mL of synthetic Caenorhabditis elegans miR-39 (cel-miR-39, 10 nM) to validate
the efficiency of RNA extraction. Then, RNA was extracted using QIAzol Lysis
Reagent (Qiagen) in combination with miRNeasy mini kit (Qiagen). One mL
QIAZOL was added to 200 mL of plasma and homogenized by vigorous mixing on a
vortex (15 seconds) and then incubated at RT for 5 minutes. Next, 200 mL
Chloroform were added and mixed on a vortex for 10 seconds followed by incubation
at RT for 2 minutes. Samples were then centrifuged at 12000 3 g and 4uC for 15
minutes. The upper (aqueous) phase was transferred to a new RNase-free tube and
20 mL Glycogen (Ambion) plus 1.5 vol. ethanol were added. After that, the protocol
was performed using the miRNeasy mini kit (Qiagen) and according to the
manufacturer’s instructions. Briefly, 750 mL of the samples were transfered to a
RNeasy Mini Spin Column, centrifuged at 13000 3 g for 30 seconds at RT and the
flow through was discarded. This step was repeated with the remaining sample and
then the column was washed once with 700 ml RWT buffer and next 3 times with RPE
buffer.
Finally, RNA was eluted by adding 30 ml of DNase/RNase-free water to the column
and centrifuged at 13000 3 g for 1 minute at RT. Eluted RNA samples were stored at
280uC until use. Quantitation of cel-miR-39 by qRT-PCR was performed in quad-
ruplicate using human TaqMan MicroRNA Assay Kits (Applied Biosystems) on a
Corbett Rotorgene rotorcycler (Qiagen, Germany) (Supplemental figure 1a).
Isolation of RNA from cells. RNA was isolated from cells using Trizol-chloroform
extraction followed by isopropanol precipitation of the aequeous phase and
centrifugation at 12.000 3 g for 15 minutes at 4uC. Precipitated total RNA was
washed once with 70% Ethanol and dried prior to resuspension in 30 ml nuclease-free
water. RNA concentration was determined using a NanoDrop 1000
spectrophotometer (Thermo Scientific) and stored at 280uC.
Real-time qPCR analysis of circulating microRNAs. miRNA expression profiling
was performed by Exiqon Inc., Denmark using an LNA qPCR Array platform and the
commercially available serum/plasma miRNA focus panel in 384-well format.
In order to evaluate the reverse transcription efficiency, prior to the reverse tran-
scription step synthetic RNA oligonucleotides (RNA spike-in, UniSp6) were added to
all samples (Supplemental figure 1b). Then, 15 ml RNA were reverse transcribed in
75 ml volume reactions using the miRCURY LNATM Universal RT miRNA PCR,
Polyadenylation and cDNA synthesis kit (Exiqon). At this step, a synthetic DNA
spike-in (UniSp3) was added to all the cDNA samples (Supplemental figure 1b).
Subsequently, cDNA was diluted and assayed in 10 ml PCR reactions according to the
protocol for miRCURY LNATM Universal RT miRNA PCR Human serum/plasma
focus panel. Negative controls excluding template from the reverse transcription
reaction were performed and profiled similar to the samples. qPCR amplifications
were performed in 384-well plates, in a LightCyclerH 480 Real-Time PCR System
(Roche). The determination of Crossing point (Cp) and melting curve analysis were
done using the Roche LC software and the 2nd derivative method.
In order to evaluate whether the samples were affected by haemolysis46, the dif-
ferences between the expression of hsa-miR-23a and hsa-miR-451 were calculated. A
cutoff of 8 was imposed according to the literature, with ddCp values ,8 and .8
indicating low or high risk of sample contamination by haemolysis, respectively47
(Supplemental figure 1c). In order to assess the state of liver toxicity in all patient RNA
samples, hsa-miR-122 expression levels were evaluated and log2 fold change against
hsa-miR-23a was calculated (Supplemental figure 1d).
Data analysis. All the amplified miRNAs were analyzed for distinct melting curves
and the Tm was checked to be within known specifications for the assay.
Furthermore, only assays detected with 5 Cp’s less than the negative control, and with
Cp , 37 were included in the data analysis.
Normalization was performed using the average of miRNAs detected in all sam-
ples, an approach that has previously been reported to produce reliable results48.
Additionally, the normfinder algorithm49 confirmed that the stability of the average
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Cp-value of the 96 miRNAs is higher than the stability of any single miRNA in the
data set (see Supplemental table 3 for details). Normalized Cp values (dCp) were
calculating using the follow formula:
Normalized Cp~average Cp n~96 assaysð Þ{assay Cp sampleð Þ
Where a higher value indicates that a determined miRNA is more abundant in the
analyzed sample.
Power analysis. A basic power analysis calculation was performed, to assess the
control of type-II errors during such a high-throughput approach to miRNA
screening in plasma samples. Therefore, the distribution of standard deviations of all
175 miRNAs that were included was analyzed (Supplemental Figure 4A). The median
SD amounted to 1.67. This value was chosen for calculation of sample sizes that are
required to detect a certain size effect (delta Ct difference between two groups)
depending on Power and significance level a (kept constant at 0.05). The results are
shown as line plot and table in Supplemental Figure 4 (B,C).
Real-time qPCR analysis of cellular microRNAs. Two ml of total RNA that had been
diluted to 5 ng/ml were reverse transcribed using the Universal cDNA Synthesis Kit
together with UniSp6 spike-in control to monitor the presence of enzyme inhibitors.
Real-time qPCR reactions were performed in 10 ml reaction volumes in triplicates
using SYBR Green Mix (Exiqon Inc.) together with commercially available primer
assays for hsa-miR-146a, hsa-miR-29b-3p and hsa-miR-33a-5p and U6 and 5S rRNA
as reference RNAs, respectively. PCR conditions were 95uC for 10 minutes, 45 cycles
of denaturation (95uC, 10 s) and annealing/elongation (60uC, 60 s), and melting
curve analysis on an LC 480 (Roche). Cp-values were calculated using the 2nd
derivative method and ddCt analysis was performed to calculate log2-fold differences
between control- and mRNA-transfected samples.
In vitro experiments. miRNA overexpression. MT-2 T-cell line was obtained from the
AIDS Research and Reference Reagent program (AIDS Division, National Institute of
Allergy and Infectious Disease, National Institutes of Health). For miRNA
transfection, 3 3 104 cells per well were seeded on a 24-well plate and transfected with
25 nM pre-miRs precursors (hsa-miR-29b-3p, hsa-miR-146a-5p, hsa-miR-33a-5p)
(Ambion) or Pre-miR miRNA Negative Control (non-targeting miR control)
(Ambion) using siPort NeoFx transfection reagent (Invitrogen).
Transfection of primary CD4-positive T cells. CD4-positive T cells were isolated from
PBMCs with magnetic beads from Miltenyi (Cat.# 130-091-301) as recommended by
the manufacturer. Immediately after isolation, cells (1 3 106/reaction) were trans-
fected with 150 nM pre-miRs precursors (hsa-miR-29b-3p, hsa-miR-146a-5p, hsa-
miR-33a-5p) (Ambion) or hsa-miR-10a-5p (a non-functional control) (Ambion)
using an Amaxa Human T cell Nucleofector Kit (Lonza VPA 1002) as recommended
by the manufacturer with the transfection protocol U-014. Transfection efficiency
was optimized using Cy-3 labeled non-targeting controls. Efficiencies of 62% positive
cells were achieved (Supplemental Figure 4).
HIV in vitro infection. The HIV-NL4.3 viral strain was obtained from the NIH (AIDS-
directed Program). Forty eight hours after transfection, MT-2 cells were infected with
2 ul of the viral stock (multiplicity of infection 2.8 3 104) and incubated for 3 h hours
at 37uC. Alternatively IL-2 and PHA- stimulated primary CD4-positive T cells were
used for infection (multiplicity of infection 3 3 105). Then, the cells were washed and
resuspended in RPMI medium supplemented with 10% FBS. MT-2 cell culture
supernatants were harvested at days 3, 6 and 9 post-infection, primary CD4 T-cells on
days 4, 8, 11 and 14. The replication kinetics were examined by measuring the levels of
p24 using an ELISA kit (provided by Polymun) as described recently50.
Flow cytometry. MT-2 cells were seeded in RPMI medium (supplemented with 10%
FBS) in a concentration of 3 3 105 cells per well on a 24-well plate and transfected
with pre-miRs precursor hsa-miR-146a-5p (Ambion) or pre-miRmiRNA negative
Control (non-targeting miR control) (Ambion) according to protocol described
above. After 24 hour-incubation at 37uC, 5% CO2 the cells were transferred into
FACS tubes, washed and incubated with staining antibodies against CXCR4 (BD PE
mouse anti-human CD184, Lot: 54058) for 30 minutes in dark at 4uC. After another
washing step the cells were resuspended in 500 ml PBS and analyzed for expression of
CXCR4 using BD Biosciences FACS Canto II cytometer.
Statistical analysis. Descriptive analysis. Heatmap, unsupervised hierarchical
clustering and principal component analysis (PCA) were used to visualize patterns in
the data set. Heatmap was produced using Euclidean distance and the hierarchical
clustering by complete linkage using the heatmap.2 function in R/Bioconductor51.
Heatmap and unsupervised hierarchical clustering were performed on the 96
miRNAs expressed in all the samples, while the PCA was performed on all the
samples.
Inferential analysis. Chi Square test was used for evaluating differences in gender
distribution between the groups. For studying the differences in CD41 T cell levels
and known time of infection between EC and CH, t-test was used. For analyzing the
statistical significance of the infection assay and comparing dCp and age between
groups one-way ANOVA followed by Bonferroni multiple-comparison post-hoc test
were performed. Additionally, the false discovery rate (FDR) adjustment was used to
control the error rate of the relative miRNAs expression. The FDR (q-values) # 0.05
were considered significant52. Pearson correlation was used to determine the mag-
nitude of association between the dCp and T CD4 1 cell counts. The p-values # 0.05
were considered significant.
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